Trial Profile
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 01 Dec 2023
Price :
$35
*
At a glance
- Drugs Upadacitinib (Primary) ; Corticosteroids
- Indications Atopic dermatitis
- Focus Registrational; Therapeutic Use
- Acronyms AD Up
- Sponsors AbbVie; AbbVie Germany; Sumitomo Pharma America
- 11 Oct 2023 According to AbbVie media release, data from this study will be orally presented at the 32nd European Academy of Dermatology and Venereology (EADV) Congress
- 11 Oct 2023 Results published in the AbbVie Media Release
- 05 Oct 2023 Planned End Date changed from 16 Nov 2025 to 16 Nov 2030.